Lyell Immunopharma, Inc. (LYEL)
22.71
+0.07
(+0.31%)
USD |
NASDAQ |
Feb 06, 16:00
22.72
+0.02
(+0.07%)
After-Hours: 20:00
Lyell Immunopharma EPS Diluted (Quarterly) : -2.126 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Insmed, Inc. | -1.747 |
| Nektar Therapeutics | -1.875 |
| GT Biopharma, Inc. | -0.8268 |
| Ionis Pharmaceuticals, Inc. | -0.805 |
| Regeneron Pharmaceuticals, Inc. | 7.857 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -38.85M |
| Revenue (Quarterly) | 0.015M |
| Total Expenses (Quarterly) | 38.86M |
| Enterprise Value | 69.74M |
| Gross Profit Margin (Quarterly) | -17.01K% |
| Profit Margin (Quarterly) | -259.0K% |
| Earnings Yield | -86.26% |
| Normalized Earnings Yield | -52.86 |